These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 16621459)
1. Antiviral activity of cyclosaligenyl prodrugs of the nucleoside analogue bromovinyldeoxyuridine against herpes viruses. Meerbach A; Meier C; Sauerbrei A; Meckel HM; Wutzler P Int J Antimicrob Agents; 2006 May; 27(5):423-30. PubMed ID: 16621459 [TBL] [Abstract][Full Text] [Related]
2. In vitro activity of cycloSal-nucleoside monophosphates and polyhydroxycarboxylates against orthopoxviruses. Sauerbrei A; Meier C; Meerbach A; Schiel M; Helbig B; Wutzler P Antiviral Res; 2005 Sep; 67(3):147-54. PubMed ID: 16076502 [TBL] [Abstract][Full Text] [Related]
3. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU). De Clercq E Med Res Rev; 2005 Jan; 25(1):1-20. PubMed ID: 15389733 [TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene. Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Shimizu K; Seno T Mol Pharmacol; 1987 Sep; 32(3):410-6. PubMed ID: 2823092 [TBL] [Abstract][Full Text] [Related]
5. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene. Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Seno T Mol Pharmacol; 1985 Dec; 28(6):581-7. PubMed ID: 3001499 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. Russ P; Schelling P; Scapozza L; Folkers G; Clercq ED; Marquez VE J Med Chem; 2003 Nov; 46(23):5045-54. PubMed ID: 14584954 [TBL] [Abstract][Full Text] [Related]
7. Characterization and susceptibility to antiviral agents of herpes simplex virus type 1 containing a unique thymidine kinase gene with an amber codon between the first and the second initiation codons. Saijo M; Suzutani T; Mizuta K; Kurane I; Morikawa S Arch Virol; 2008; 153(2):303-14. PubMed ID: 18066636 [TBL] [Abstract][Full Text] [Related]
8. Carbocyclic 5-iodo-2'-deoxyuridine (C-IDU) and carbocyclic (E)-5-(2-bromovinyl)-2'-deoxyuridine (C-BVDU) as unique examples of chiral molecules where the two enantiomeric forms are biologically active: interaction of the (+)- and (-)-enantiomers of C-IDU and C-BVDU with the thymidine kinase of herpes simplex virus type 1. Balzarini J; De Clercq E; Baumgartner H; Bodenteich M; Griengl H Mol Pharmacol; 1990 Mar; 37(3):395-401. PubMed ID: 2156153 [TBL] [Abstract][Full Text] [Related]
9. Selection of HSV-1 TK gene-transfected murine mammary carcinoma cells resistant to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and ganciclovir (GCV). Degrève B; De Clercq E; Balzarini J Gene Ther; 2000 Sep; 7(18):1543-52. PubMed ID: 11021592 [TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of cycloSaligenyl-nucleoside monophosphates (cycloSal-NMP) of acyclic nucleoside analogues on HSV-1 and EBV. Meerbach A; Klöcking R; Meier C; Lomp A; Helbig B; Wutzler P Antiviral Res; 2000 Jan; 45(1):69-77. PubMed ID: 10774591 [TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase. Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629 [TBL] [Abstract][Full Text] [Related]
12. Potential of bromovinyldeoxyuridine in anticancer chemotherapy. De Clercq E Anticancer Res; 1986; 6(4):549-56. PubMed ID: 3752935 [TBL] [Abstract][Full Text] [Related]
13. Selective virus inhibitors. De Clercq E Microbiologica; 1990 Apr; 13(2):165-78. PubMed ID: 1693749 [TBL] [Abstract][Full Text] [Related]
14. (Z)- and (E)-2-(hydroxymethylcyclopropylidene)-methylpurines and pyrimidines as antiviral agents. Qiu YL; Ptak RG; Breitenbach JM; Lin JS; Cheng YC; Kern ER; Drach JC; Zemlicka J Antivir Chem Chemother; 1998 Jul; 9(4):341-52. PubMed ID: 9875413 [TBL] [Abstract][Full Text] [Related]
15. 5-Iodo-2'-deoxy-L-uridine and (E)-5-(2-bromovinyl)-2'-deoxy-L-uridine: selective phosphorylation by herpes simplex virus type 1 thymidine kinase, antiherpetic activity, and cytotoxicity studies. Spadari S; Ciarrocchi G; Focher F; Verri A; Maga G; Arcamone F; Iafrate E; Manzini S; Garbesi A; Tondelli L Mol Pharmacol; 1995 Jun; 47(6):1231-8. PubMed ID: 7603465 [TBL] [Abstract][Full Text] [Related]
16. [(E)-5-(2-bromovinyl)-2'-desoxyuridine--a new nucleoside analog with selective inhibitory action against herpesviruses. Studies in cell culture and animal experiments]. Reefschläger J; Wutzler P; Thiel KD; Töpke H; Bärwolff D; Langen P Pharmazie; 1987 Jun; 42(6):407-11. PubMed ID: 2823299 [TBL] [Abstract][Full Text] [Related]
17. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. De Clercq E Biochem Pharmacol; 2004 Dec; 68(12):2301-15. PubMed ID: 15548377 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides. Balzarini J; McGuigan C Biochim Biophys Acta; 2002 Jul; 1587(2-3):287-95. PubMed ID: 12084470 [TBL] [Abstract][Full Text] [Related]
19. Methotrexate potentiates anti-herpes simplex virus type 1 activity of E-5-(2-bromovinyl)-2'-deoxyuridine. Pancheva SN Acta Virol; 1995 Apr; 39(2):117-9. PubMed ID: 7676937 [TBL] [Abstract][Full Text] [Related]
20. Comparative inhibition of DNA polymerases from varicella zoster virus (TK+ and TK-) strains by (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate. Yokota T; Konno K; Shigeta S; De Clercq E Mol Pharmacol; 1984 Sep; 26(2):376-80. PubMed ID: 6090888 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]